- P-ISSN 1225-0163
- E-ISSN 2288-8985
- 권한신청
- P-ISSN1225-0163
- E-ISSN2288-8985
- SCOPUS, ESCI, KCI
논문 상세
Home > 논문 상세
Spectrofluorometric quantification of Clozapine in pharmaceutical formulations and human plasma
분석과학 / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
2022, v.35 no.1, pp.24-31
https://doi.org/10.5806/AST.2022.35.1.24
(Chemistry Department, College of Science, Babylon University & Al-mustaqbal University College)
(Chemistry Department, College of Science, Babylon University)
(Chemistry Department, College of Science, Babylon University)
(Chemistry Department, College of Science, Babylon University)
(Chemistry Department, College of Science, Babylon University)
Ali,
F.
M.
,
AN,
A.
,
&
Kasim,
H.
K.
(2022). . 분석과학, 35(1), 24-31, https://doi.org/10.5806/AST.2022.35.1.24
- 다운로드 수
- 조회수
Abstract
Herein, we present a simple, precise, accurate, and ultra-sensitive spectrofluorimetric method for estimation of clozapine (CLZ) in tablets and human plasma was developed and then validated. A highly fluorescent brown-yellowish fluorophore was formed (λex=469 nm, λemi=540 nm) as a nucleophilic substitution reaction occurred between CLZ and 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) in alkaline mcllavine buffer (pH 9.0). Optimum values of experimental parameters were carefully determined and optimized. The calibration curve was rectilinear over the concentration range of 80-900 ng mL−1 with a linear correlation coefficient (r =0.9984). The LOD and LOQ were determined to be 14 ng mL−1 and 42 ng mL−1, respectively. The proposed approach has been used successfully to quantification of Clozapine in its commercial formulations and human plasma.
- keywords
- clozapine, NBD-Cl, spectrofluorimetric, human plasma
참고문헌
1
1. M. W. Jann, Pharmacother. J. Hum. Pharmacol. Drug Ther., 11(3), 179-195 (1991).
2
2. M. G. Choc, F. Hsuan, G. Honigfeld, W. T. Robinson, L. Ereshefsky, M. L. Crismon, S. R. Saklad, J. Hirschowitz and R. Wagner, Pharm. Res., 7(4), 347-351 (1990).
3
3. M. A. Raggi, V. Pucci, F. Bugamelli and V. Volterra, J. AOAC Int., 84(2), 361-367 (2001).
4
4. A. Essali, N. A. H. Haasan, C. Li and J. Rathbone, Cochrane Database Syst. Rev., 2009(1), 1-174 (2009).
5
5. D. Siskind, L. McCartney, R. Goldschlager and S. Kisely, Br. J. Psychiatry, 209(5), 385-392 (2016).
6
6. P. B. Mitchell, in ‘Therapeutic drug monitoring of antidepressant and antipsychotic drugs’, Vol. 7, p257-275, Elsevier, 2020.
7
7. J. M. J. Alvir, J. A. Lieberman, A. Z. Safferman, J. L. Schwimmer and J. A. Schaaf, NEJM, 329(3), 162-167(1993).
8
8. F. Islam, D. Hain, D. Lewis, R. Law, L. Brown, J.-A. Tanner and D. J. Mueller, Biol. Psychiatry, 89(9), S341(2021).
9
9. N. Tunsirimas, P. Pariwatcharakul, S. Choovanichvong and W. Ratta-Apha, Asian J. Psychiatr., 41, 13-16(2019).
10
10. S. Rajagopal, in ‘Clozapine, agranulocytosis, and benign ethnic neutropenia’, The Fellowship of Postgraduate Medicine, 2005.
11
11. M. Hasegawa, P. A. Cola and H. Y. Meltzer, Neuropsychopharmacology, 11(1), 45-47 (1994).
12
12. M. Wiciński and M. M. Węclewicz, Curr. Opin. Hematol., 25(1), 22-28 (2018).
13
13. S. L. Gerson and H. Meltzer, Drug Safety, 7(1), 17-25(1992).
14
14. W. Ng, R. Kennar and J. Uetrecht, Chem. Res. Toxicol., 27(7), 1104-1108 (2014).
15
15. B. A. Sproule, C. A. Naranjo, K. E. Bremner and P. C. Hassan, Clin. Pharmacokinet., 33(6), 454-471 (1997).
16
16. U. A. Patil and B. Ghosh, Int. J. Pharm. Tech. Res., 1, 733-736 (2009).
17
17. https://go.drugbank.com/drugs/DB00363.
18
18. H. Ben-Yoav, S. E. Chocron, T. E. Winkler, E. Kim, D. L. Kelly, G. F. Payne and R. Ghodssi, Electrochim. Acta., 163, 260-270 (2015).
19
19. K. Farhadi and A. Karimpour, Anal. Sci., 23(4), 479-483 (2007).
20
20. U. Bondesson and L. H. Lindström, Psychopharmacology, 95(4), 472-475 (1988).
21
21. M. Rosland, P. Szeto, R. Procyshyn, A. M. Barr and K. M. Wasan, Drug Dev. Ind. Pharm., 33(10), 1158-1166(2007).
22
22. M. Raggi, F. Bugamelli, R. Mandrioli, D. De Ronchi and V. Volterra, Chromatographia, 49(1-2), 75-80 (1999).
23
23. Y. Liu, L. D. van Troostwijk and H. J. Guchelaar, Biomed. Chromatogr., 15(4), 280-286 (2001).
24
24. C. Wongsinsup, W. Taesotikul, S. Kaewvichit, S. Sangsrijan and S. Sangsrija, CMU. J. Nat. Sci., 9, 29-37 (2010).
25
25. E. Schulz, C. Fleischhaker and H. Remschmidt, Pharmacopsychiatry, 28(01), 20-25 (1995).
26
26. K. Manjunatha and V. Venkateshwarlu, Indian J. Pharm. Sci., 67(4), 448 (2005).
27
27. H. Weigmann, J. Bierbrauer, S. Härtter and C. Hiemke, Ther. Drug Monit., 19(4), 480-488 (1997).
28
28. E. Dural, G. MERGEN and T. SÖYLEMEZOĞLU, Turkish J. Pharm. Sci., 12(2), 177-186 (2015).
29
29. S. Mennickent, A. Sobarzo, M. Vega, C. G. Godoy and M. de Diego, J. Sep. Sci., 30(13), 2167-2172 (2007).
30
30. A. Avenoso, G. Facciolà, G. M. Campo, A. Fazio and E. Spina, J. Chromatogr. B Biomed. Appl., 714(2), 299-308 (1998).
31
31. A. M. Eldidamony, S. M. Hafeez and M. M. A. Hafez, Int. J. Pharm., 7(1), 178-184 (2015).
32
32. M. R. Fathi and D. Almasifar, IEEE Sens. J., 17(18), 6069-6076 (2017).
33
33. E. Reyhan, S. YILMAZ, S. YAĞMUR and Ö. T. YAYINTAŞ, J. Sci. Perspect., 1(2), 19-30 (2017).
34
34. K. A. Attia, A. El-Olemy, S. Ramzy, A. H. Abdelazim, M. A. Hasan, M. K. Omar and M. Shahin, Spectrochim. Acta A Mol. Biomol. Spectrosc., 244, Article 118871(2021).
35
35. Guideline, I. Q2 (R1): validation of analytical procedure:text and methodology. ICH, London 2005.
36
36. A. Ayman, A. M. Zeid, M. Wahba and E.-S. Yasser, Spectrochim. Acta A Mol. Biomol. Spectrosc., 238, Article 118447 (2020).
권호 내 다른 논문
- Mixture of dimethylaminobenzaldehyde and cyanoacrylate to develop fingerprints with fluorescence: a preliminary test
- An Analysis of the proteomics approach to the glycated peptides of human milk
- Monitoring of heavy metals, bisphenol A and phenol migrated from food packages for delivery
- Spectrofluorometric quantification of Clozapine in pharmaceutical formulations and human plasma
- Concentration variability of atmospheric radon and gaseous pollutants at background area of Korea between 2017 and 2018
- more
추천 논문
학술지 홈페이지 이용 환경은 크롬 브라우저 사용을 권장합니다.